Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
114.74
-1.25 (-1.08%)
At close: Mar 4, 2025, 4:00 PM
114.81
+0.07 (0.06%)
After-hours: Mar 4, 2025, 6:46 PM EST
Gilead Sciences Employees
Gilead Sciences had 17,600 employees as of December 31, 2024. The number of employees decreased by 400 or -2.22% compared to the previous year.
Employees
17,600
Change (1Y)
-400
Growth (1Y)
-2.22%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
142.89B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 17,600 | -400 | -2.22% |
Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
Dec 31, 2021 | 14,400 | 800 | 5.88% |
Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
Jan 31, 2015 | 7,000 | 900 | 14.75% |
Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
Jan 31, 2013 | 5,000 | 500 | 11.11% |
Jan 31, 2012 | 4,500 | 500 | 12.50% |
Jan 31, 2011 | 4,000 | 148 | 3.84% |
Jan 31, 2010 | 3,852 | 411 | 11.94% |
Jan 31, 2009 | 3,441 | 462 | 15.51% |
Jan 31, 2008 | 2,979 | 464 | 18.45% |
Jan 31, 2007 | 2,515 | 615 | 32.37% |
Jan 31, 2006 | 1,900 | 246 | 14.87% |
Feb 28, 2005 | 1,654 | 229 | 16.07% |
Feb 27, 2004 | 1,425 | 175 | 14.00% |
Feb 28, 2003 | 1,250 | 250 | 25.00% |
Feb 28, 2002 | 1,000 | 150 | 17.65% |
Feb 28, 2001 | 850 | 90 | 11.84% |
Dec 31, 1999 | 760 | 467 | 159.39% |
Dec 31, 1998 | 293 | 4 | 1.38% |
Dec 31, 1997 | 289 | 41 | 16.53% |
Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
GILD News
- 6 hours ago - Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript) - Seeking Alpha
- 13 hours ago - Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025 - Invezz
- 1 day ago - Gilead Sciences sets aside $200 million to resolve HIV drug probe - Reuters
- 5 days ago - Why Gilead Sciences Remains A Buy After A 40% Rally - Seeking Alpha
- 7 days ago - MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gilead's Trodelvy® in Advanced Breast Cancer - Business Wire
- 8 days ago - European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention - Business Wire
- 12 days ago - Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis - Business Wire
- 13 days ago - Gilead Sciences to Present at Upcoming Investor Conferences - Business Wire